Ad hoc: Epigenomics AG: Ad hoc Announcement According to Section 15 WpHG (German Securities Trading Act): Epigenomics AG Signs Strategic R&D Collaboration Agreement in Colorectal Cancer with Sysmex Corporation

• Press Release
• Source: Epigenomics AG
• On 1:11 am EST, Thursday January 22, 2009

BERLIN, Jan. 22, 2009 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX.F - News) (ISIN: DE000A0BVT96) today signed a strategic research and development collaboration agreement in molecular diagnostics with Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu).

Related Quotes

Symbol	Price	Change
ECX.F	3.38	-0.05

{"s" : "ecx.f,epgnf.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Under the terms of the agreement, Sysmex and Epigenomics will assess the suitability of Sysmex' molecular diagnostics instrumentation for the detection of DNA methylation cancer biomarkers in blood. As a benchmark for the development of its assay system, Sysmex will use Epigenomics' mSEPT9 Methylation Detection Assay commercially available as a research use only product. If successful, Sysmex intends to develop and commercialize initially in Japan a blood test for the early detection of colorectal cancer based on Epigenomics' proprietary SEPT9 DNA Methylation Biomarker (mSEPT9). Upon entering into this collaboration both parties have started negotiations for a non-exclusive mSEPT9 licensing agreement.

Under the terms of the collaboration agreement, Sysmex gets access to Epigenomics' technologies through R&D licenses and technology transfer and will be supported by Epigenomics in its R&D work. In return, Epigenomics will receive certain license fees, R&D funding and reimbursements and will sell its mSEPT9 research use only product to Sysmex.

End of Ad hoc

Further Information

For further information please see the joint press release issued today by Sysmex Corporation and Epigenomics AG at http://www.epigenomics.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

          Epigenomics AG 
          Dr. Achim Plum, Sen. VP Corporate Development 
          +49 30 24345 368 
          Fax: +49 30 24345 555 
          achim.plum@epigenomics.com 
          www.epigenomics.com